![free clinical trials and research for copd at duke free clinical trials and research for copd at duke](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41533-019-0123-0/MediaObjects/41533_2019_123_Fig1_HTML.png)
#Free clinical trials and research for copd at duke trial
Enrolling 463 patients with platinum-resistant or refractory ovarian cancer-more than 30 of whom were from Duke-the trial had a high response rate in women with BRCA mutations (31 percent overall), including patients with platinum-sensitive (39 percent), resistant (33 percent), and refractory (19 percent) disease. QUADRA : A single-arm, multicenter phase 2 trial evaluating safety and efficacy of niraparib as fourth or later line of therapy. Hopefully the many ongoing studies will lead to personalized precision medicine approaches and help us treat our patients with the right drug(s) at the right time.”ĭuke was involved in several recent clinical trials that were presented at the European Society of Medical Oncology meeting in October 2018. “Now, more than ever, we have options-notably targeted agents like PARP inhibitors-for patients with platinum-sensitive and platinum-recurrent disease.”Īngeles Alvarez Secord, MD, MHS, gynecologic oncologist and director of Gynecologic Oncology Clinical Trials at Duke agrees, adding: “We are moving toward combining these exciting agents (anti-angiogenics, PARP inhibitors, and immunotherapies) together or with chemotherapy in a rational manner. “It’s an exciting time for ovarian cancer research,” says Duke gynecologic oncologist Rebecca Previs, MD, MS, who serves as Duke’s liaison for Phase 1 Gynecologic Clinical Trials. New treatment options and drug combinations continue to emerge and many are being tested in clinical trials. Immunotherapies, which have been game changers for cancers with a high mutational load like melanoma and lung cancer, have shown modest effects in ovarian cancer.
![free clinical trials and research for copd at duke free clinical trials and research for copd at duke](https://www.lung.org/getmedia/866e5a0e-ff78-4cd7-8a29-5d43d07c87b5/acrc-map-2020_p.jpg)
Anti-angiogenics and poly(ADP-ribose)polymerase (PARP) inhibitors have demonstrated promising anti-tumor activity and prolonged survival for select patients. Ovarian cancer has historically had few effective treatment options, particularly for patients with advanced or platinum-resistant disease.